Open

Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

This is a study for people with colon, pancreatic, Squamous Non-small cell lung cancer, or Squamous cell carcinoma of head and neck. In this study, we want to find out if an investigational drug (Tisotumab Vedotin) is effective for people with solid tumors.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will be given the study drug through an infusion. You will be given test and procedures as part of the study to test the efficiency and safety of the drug.

Incentives

Gas and Travel Reimbursement

Total length of participation:
Until Disease Progression or voluntary withdrawal.

Looking for Specific Volunteers

Able to participate:

You have colon, pancreatic, Squamous NSCLC, or SCCHN cancer
You have a life expectancy of 3 months or more
You have had previous cancer treatment

Not eligible if:

You have an increased risk of bleeding
You have heart disease
You have had another cancer within the past 3 years
You have had major surgery within the past 4 weeks
You have active eye disease

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Shetal Patel
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

19-0031

ClinicalTrials.gov

NCT03175224

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.